10/15/2025
A recent editorial in the American Society of Clinical Oncology Journal of Clinical Oncology highlights an urgent truth for blood cancer patients: how quickly a bone marrow transplant can be performed is as critical as HLA matching.
Referencing results from the BMT CTN 1702 study, author Alessandro Rambaldi, MD emphasizes that for high-risk blood cancers like acute leukemia, faster access to a donor can make the difference between cure and relapse:
“When the risk of relapse is high, as in the case of acute leukemia patients, the shorter the time to transplant, the better the outcome. This seems particularly important, for urgent cases for whom a timeline of 6 weeks or less from unrelated search initiation to graft infusion should be considered ideal. Accordingly, disease biology, patient-related variables, and keeping the time to transplant as short as possible are more important than waiting for a better HLA-matched donor.”
At Ossium Health, we’re making that rapid access a reality. Our cryopreserved bone marrow banking platform ensures donors are available on demand, enabling bone marrow transplants to be performed within 72 hours of the initial donor search.
Read the full editorial in JCO:
🔗
Partial AccessEDITORIALSSeptember 30, 2025 Share on Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus PerdereAuthor: Alessandro Rambaldi, MD https://orcid.org/0000-0002-3739-7502 [email protected]Authors Info & AffiliationsPublication: Journal of Clinical OncologyNewest ...
